A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.

Kei SaitoYousuke NakaiNaminatsu TakaharaKazunaga IshigakiYukari SuzukiAkiyuki InokumaKensaku NoguchiSachiko KanaiTatsuya SatoRyunosuke HakutaTomotaka SaitoTsuyoshi HamadaSuguru MizunoHirofumi KogureHideaki IjichiKeisuke TateishiKazuhiko Koike

Published in: Investigational new drugs (2020)

S-IROX and mFFX were similarly tolerable and effective as a second-line chemotherapy in patients with PC refractory to gemcitabine plus nab-paclitaxel.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
advanced non small cell lung cancer
radiation therapy
chemotherapy induced
epidermal growth factor receptor